Jens Bedke
Katharinenhospital · 636 works · 28,432 citations · h-index 58
Top works
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
- European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update
- Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
- Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
- Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
- Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
- Economic aspects of bladder cancer: what are the benefits and costs?
- Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma
- Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
- Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update
- Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial
- Systemic therapy in metastatic renal cell carcinoma
- Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma
- Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer